Q-Cells

About Q Therapeutics

Q Therapeutics is a private, clinical-stage biotech based in Salt Lake City, pioneering a novel glial cell replacement therapy for neurodegenerative and demyelinating diseases. The company's platform utilizes purified human glial progenitor cells (Q-Cells®) as an off-the-shelf, non-genetically manipulated therapeutic to address the underlying causes of CNS disorders. With an FDA-allowed IND for a Phase 1/2a trial in Transverse Myelitis and a broad potential pipeline including ALS and multiple sclerosis, Q Therapeutics is positioned to target significant unmet medical needs in neurology. The company is led by CEO Steve Borst and leverages a strong intellectual property portfolio of over 20 issued patents.

About Q Therapeutics

Q Therapeutics is a private, clinical-stage biotech based in Salt Lake City, pioneering a novel glial cell replacement therapy for neurodegenerative and demyelinating diseases. The company's platform utilizes purified human glial progenitor cells (Q-Cells®) as an off-the-shelf, non-genetically manipulated therapeutic to address the underlying causes of CNS disorders. With an FDA-allowed IND for a Phase 1/2a trial in Transverse Myelitis and a broad potential pipeline including ALS and multiple sclerosis, Q Therapeutics is positioned to target significant unmet medical needs in neurology. The company is led by CEO Steve Borst and leverages a strong intellectual property portfolio of over 20 issued patents.

About Q Therapeutics

Q Therapeutics is a private, clinical-stage biotech based in Salt Lake City, pioneering a novel glial cell replacement therapy for neurodegenerative and demyelinating diseases. The company's platform utilizes purified human glial progenitor cells (Q-Cells®) as an off-the-shelf, non-genetically manipulated therapeutic to address the underlying causes of CNS disorders. With an FDA-allowed IND for a Phase 1/2a trial in Transverse Myelitis and a broad potential pipeline including ALS and multiple sclerosis, Q Therapeutics is positioned to target significant unmet medical needs in neurology. The company is led by CEO Steve Borst and leverages a strong intellectual property portfolio of over 20 issued patents.

About Q Therapeutics

Q Therapeutics is a private, clinical-stage biotech based in Salt Lake City, pioneering a novel glial cell replacement therapy for neurodegenerative and demyelinating diseases. The company's platform utilizes purified human glial progenitor cells (Q-Cells®) as an off-the-shelf, non-genetically manipulated therapeutic to address the underlying causes of CNS disorders. With an FDA-allowed IND for a Phase 1/2a trial in Transverse Myelitis and a broad potential pipeline including ALS and multiple sclerosis, Q Therapeutics is positioned to target significant unmet medical needs in neurology. The company is led by CEO Steve Borst and leverages a strong intellectual property portfolio of over 20 issued patents.

Therapeutic Areas